Group 1 - The company held its 11th meeting of the 8th Supervisory Board on June 27, 2025, with all three supervisors present, complying with legal and procedural requirements [1][2] - The Supervisory Board approved a proposal allowing the company and its subsidiaries to borrow up to RMB 1 billion from the related party, Wuhai Junzheng Technology Industry Group Co., Ltd., to meet operational needs and improve financing efficiency [1][2] - The borrowing will be at a rate not exceeding the People's Bank of China’s loan market quotation rate, without the need for guarantees or collateral, and will be used for daily operations, project construction, and other funding needs [1][2] Group 2 - The Supervisory Board concluded that borrowing from Junzheng Technology would meet the company's operational development needs, reduce financing costs, and maintain the interests of all shareholders without violating any laws or regulations [2] - The voting result for the proposal was unanimous, with 2 votes in favor and no opposition or abstentions, representing 100% of the total votes [2]

今天大盘整体波动不大，截止到收盘，还在4.9星。 沪深300等大盘股微跌，中证500、中证1000等微涨。 前几天强势上涨的银行指数，今天下跌较多，拖累了大盘股。 消费行业也下跌。 文 | 银行螺丝钉 （转载请注明出处） 科技、医药整体上涨。 港股波动不大。 港股科技指数略微上涨。 1. 有朋友问，前段时间港股医药涨幅比较高，到了正常估值。 最近港股医药回调。 港股的医药指数有哪些？最近港股医药回到低估了么？ 医药是11个一级行业之一。 在医药行业下，有三个比较常见的子行业：医疗、生物科技、创新药。 其实还有其他子行业（例如中医药），只是这三个的基金数量多。 医疗行业， 主要是由医疗服务和医疗器械等构成。 例如，我们平时看的眼科、牙科医院，就是医疗服务；而心脏起搏器、呼吸机、注射器等属于医疗器械。 医疗行业，是目前基金数量非常多的医药子行业，指数基金和主动基金都有不少。 生物科技， 主要是投资四个领域的公司：基因诊断、生物制药、血液制品、人体生物科技。包括疫苗，也在其中。 这个指数长期收益也不错，跟医疗是同一档次的。 本身也有科技属性。像很多科技主题基金中，也有生物科技的公司。 例如港股科技指数，除了互联网， ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 再生 （ Regeneration ） ，是一种看 似有益的特性，在某些动物谱系中得以良好维持 （例如 壁虎断尾重 生，蝾螈大脑自愈 ） ，但在许多其他谱系中却在进化和物种形成过程中丧失了。 对于再生能力有限的人类、小鼠等高等哺乳动物而言，尚未实现对其器官再生能力的完全恢复，这主要是 由于对于再生失败与基因组中遗传变化之间的关联了解有限。了解动物进化过程中导致再生能力丧失或获 得的情况，将为再生医学带来新的启示。 2025 年 6 月 27 日， 北京生命科学研究所联合北京华大生命科学研究院，在国际顶尖学术期刊 Science 上发表了题为 ： Reactivation of mammalian regeneration by turning on an evolutionarily disabled genetic switch 的研究论文。 该研究基于华大自主研发的时空组学技术 Stereo-seq 和高通量测序平台 DNBSEQ-T10， 首次发现 Aldh1a2 基因的表达不足导致的 视黄酸 （RA） 合成不足是高等哺乳动物小鼠耳廓再生失败的核心机制。 在激活该 ...

Core Viewpoint - The implementation of the Private Economy Promotion Law provides a legal foundation for the sustainable and healthy development of private enterprises in China, instilling confidence in companies like Hainan Huayan [1][2]. Group 1: Legal Framework and Support - The Private Economy Promotion Law, effective from May 20, 2025, is the first fundamental law specifically aimed at promoting the development of the private economy in China [1]. - The law establishes a principle of "equal participation," which is crucial for innovative private enterprises seeking legal protection [1][2]. - It introduces a nationwide negative list system for market access, allowing various economic organizations, including private enterprises, to enter fields outside the list on an equal legal basis [3]. Group 2: Challenges and Opportunities - Despite facing challenges such as trade barriers and financing difficulties, private high-tech enterprises like Huawei and Yushutech demonstrate resilience and vitality through innovation [2]. - The law addresses issues such as market entry barriers, financing difficulties, and disadvantages in participating in research projects, which have historically hindered the growth of private enterprises [2][3]. Group 3: Financial Support and Innovation - The law mandates financial institutions to develop financial products tailored to the characteristics of private enterprises, enhancing credit supply and improving access to financing [4]. - It emphasizes the importance of intellectual property pledge financing, allowing private enterprises to secure funding for research and innovation [4]. - Hainan Huayan has successfully launched innovative products, such as collagen peptides, which have significantly increased revenue, showcasing the potential for growth through innovation [3][4]. Group 4: Market Dynamics and Competitive Strategies - The concept of "involution" in the market is addressed, with the company advocating for healthy competition that stimulates market vitality rather than destructive price wars [5]. - Hainan Huayan is exploring new applications for its products, expanding beyond traditional markets to include sports nutrition and health products for the elderly, thereby creating new market opportunities [5]. - The law's implementation is seen as a catalyst for private enterprises to leverage technological innovation and a legal business environment to ascend the value chain [5].

Core Insights - The collaboration between the Chinese Academy of Sciences (CAS) and Guangxi has led to the successful matching of scientific research with local industry needs, particularly in the marine medicine sector [1][2] - A total of 240 scientific achievements have been opened for transformation in Guangxi, covering various fields such as new generation information technology, high-end equipment, and marine agriculture [2][4] - The event resulted in 25 cooperation intention projects between CAS and Guangxi enterprises, with a signed amount nearing 90 million yuan [4][5] Group 1: Collaboration and Achievements - The CAS has a long-standing partnership with Guangxi, with significant achievements in technology transfer and innovation, including awards for environmental projects [2] - The event showcased 65 major scientific achievements and facilitated cooperation between four Guangxi companies and four CAS research institutes [2][4] - The focus on utilizing Guangxi's abundant biomass resources for global markets highlights the region's potential in biotechnology [2][3] Group 2: Economic Impact and Future Prospects - The collaboration is expected to accelerate the transformation of scientific achievements into productive forces, with a reported annual growth rate of 30% in technology transfer contracts over the past three years [5] - The partnership aims to enhance the innovation and entrepreneurial environment in Guangxi, providing robust support for the transformation and industrialization of scientific achievements [5]

美股盘初，主要行业ETF多数上涨，全球航空业ETF涨近1%，区域银行ETF、医疗业ETF涨幅居前。 | 全球航空业E ... | 22.50 | +0.20 (+0.92%) 113.34万股 | | --- | --- | --- | | US JETS | | | | 医疗业ETF - ... | 134.76 | +0.86 (+0.64%) 140.60万股 | | us XLV | | | | 区域银行ET ... | 58.49 | +0.35 (+0.60%) 81.07万股 | | us KRE | | | | 公用事业ET ... | 80.95 | +0.45 (+0.56%) 140.43万股 | | us XLU | | | | 能源业ETF - ... | 84.90 | ↑ +0.36 (+0.43%) 258.89万股 | | us XLE | | | | 日常消费品E ... | 80.56 | ↑ +0.32 (+0.40%) 207.75万股 | | us XLP | | | | 金融业ETF --- | 51.59 | +0.18 (+0.36%) 410.69万股 | ...

Core Viewpoint - Juzi Holding, the controlling shareholder of Juzi Bio, has shown confidence in the company's future by purchasing additional shares, indicating a positive outlook on the company's performance and potential growth [1] Summary by Relevant Sections - **Share Purchase Details** - Juzi Holding has acquired 1,056,600 shares of Juzi Bio since the announcement of the buyback plan on June 9, 2025, with a total investment of approximately 53.5 million HKD [1] - **Ownership Structure** - Following the share purchase, Juzi Holding now holds a total of 582 million shares, representing 54.36% of the company's total issued shares [1] - **Future Plans** - Juzi Holding may consider further increasing its stake depending on market conditions and regulatory requirements [1]

Core Insights - The Greater Bay Area is recognized as a significant hub for biotechnology innovation, possessing rich research resources, a strong industrial foundation, and an advantageous innovation environment [1][2] - The application of stem cell technology, particularly MSCs exosomes, shows potential in treating acute liver failure, which has a high mortality rate due to rapid progression and poor prognosis [1] - Cardiovascular diseases affect approximately 330 million people in China, making them a leading health threat, with recent advancements in research and clinical translation being shared by experts [1] Industry Development - The development of the biopharmaceutical industry requires collaborative efforts from various sectors, including investment and enterprise [2] - As of December 31, 2024, the number of active innovative drugs developed by Chinese companies is projected to reach 3,575, indicating a shift from "catching up" to "leading" in research and development capabilities [2] - The launch of the eighth annual selection of the top 50 biotechnology innovation enterprises aims to stimulate innovation and promote a "leading enterprise driving, tiered growth" industrial structure [2] Market Trends - The performance of innovative pharmaceutical companies in overseas transactions since 2025 has positively influenced the stock prices of A-shares and Hong Kong stocks related to innovative drugs, reflecting market optimism about the long-term value of the industry [2] - Among the top 50 enterprises from the previous selection, 49% were high-tech enterprises, and 29% were specialized and innovative enterprises, showcasing the transformation of biotechnology companies in the Greater Bay Area from technological exploration to capital advancement [2]

香港再设创投基金！ 日前，首期规模为10亿港元的香港高才创业投资基金正式启动，该基金的目标是"让更多的高才精英能 在香港找到实现梦想的舞台"，将聚焦科技、医疗、消费等前沿领域。据悉，该基金首批3亿港元已确 认。 首批3亿港元已确认投向人工智能等领域 香港高才创业投资基金由高才通人才服务协会创始会长尚海龙及多位创始合伙人共同发起。尚海龙表 示，基金的成立不仅仅是一项金融举措，更是一个推动香港高质量发展的创新实践，希望通过这个基 金，让更多的高才精英能在香港找到实现梦想的舞台，并通过资本与技术的融合，助力香港在新质经济 领域走在全球前列。 香港高才创业投资基金的设立是香港服务高才的配套措施之一。据尚海龙透露，目前基金首批3亿港元 资金已经确认，将会聚焦支持生物科技、人工智能、金融科技、高端制造业以及Web3等活动，期待特 区政府能尽快批出相关牌照。 初创企业数量超4600家多项基金计划支援创业 "高端人才通行证计划"是香港广纳五洲四海贤才的举措之一。截至2024年底，"高才通计划"共收到约 11.6万份申请，近9.2万份获批，超过7.5万名高端人才与家人抵港。 今年1月22日，香港特区政府劳工及福利局局长孙玉菡在 ...

6月26日，胡润研究院发布《2025全球独角兽榜》，列出了全球成立于2000年之后、价值10亿美元 以上的非上市公司。 数据显示，全球独角兽企业数量达到1523家，创世界新纪录，比去年增加了70家，增幅接近5%。其中， 美国以758家独角兽企业领先，占世界总数的49.77%；中国以343家独角兽企业位居第二，占世界总数 的22.52%；印度、英国等国家的独角兽企业超过60家。 全球独角兽企业超1500家 胡润研究院在全球范围内共发现了1523家独角兽企业，它们分布在52个国家的307个城市。其中，359 家独角兽的估值比去年有所上升，包括203家新独角兽。与此同时，143家公司的估值出现下降，其中52 家因估值低于10亿美元而"降级"退出独角兽行列。此外，64家去年的独角兽因"升级"退出榜单，其中34 家成功上市，30家被收购。还有1073家独角兽的估值保持稳定。这些独角兽企业的总价值达到5.6万亿美 元。 从行业领域细分来看，全球独角兽正在重塑金融服务、企业管理解决方案和医疗健康行业。77%的独角兽 公司销售软件和服务，以金融科技、软件服务和AI领域为主，而23%的独角兽公司销售实体产品，主要集 中在半导体 ...